STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Corp - INCY STOCK NEWS

Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.

Incyte Genomics Inc. (Symbol: INCY) is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of proprietary therapeutics, with a primary focus on oncology. Headquartered in Wilmington, Delaware, Incyte employs over 625 professionals across its management, discovery, clinical development, and commercial teams.

The company’s flagship product, Jakafi, is a groundbreaking treatment for rare blood cancers and graft versus host disease, developed in partnership with Novartis. Incyte has also made significant strides with its other marketed drugs, including Olumiant for rheumatoid arthritis (licensed to Eli Lilly), Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. Additionally, Incyte's first dermatology product, Opzelura, received approval in 2021 for atopic dermatitis and in 2022 for vitiligo.

Incyte’s pipeline includes a wide array of innovative oncology and dermatology programs, demonstrating their commitment to addressing serious unmet medical needs. The company's strategic collaborations with major pharmaceutical firms further support the clinical development and global commercialization of its compounds.

Incyte’s financial health and robust portfolio position it strongly to continue improving patient lives while building sustainable value for its shareholders. For the latest updates on Incyte’s projects and developments, visit their corporate website at www.incyte.com.

News

Incyte to Report Fourth Quarter and Year-End 2023 Financial Results

Rhea-AI Summary
Incyte (Nasdaq:INCY) has scheduled its Q4 & YE 2023 financial results conference call and webcast for February 13, 2024. The press release will be at 7:00 a.m. ET, followed by the conference call at 8:00 a.m. ET. The company will provide a domestic and international dial-in number, along with a conference ID number for participation. A replay of the conference call will be available for thirty days, and the webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences earnings
-
News

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Incyte (INCY) highlights growth opportunities and provides key updates across its investigational pipeline and commercial portfolio at the 42nd Annual J.P. Morgan Healthcare Conference. The company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura®) in adults with hidradenitis suppurativa (HS) and preliminary results from Phase 1 study of INCB123667 (CDK2i). The presentation underscores potential high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
News

Incyte to Present at Upcoming Investor Conferences

Rhea-AI Summary
Incyte (Nasdaq:INCY) will present at the Goldman Sachs Annual Healthcare CEOs Unscripted Conference on January 4, 2024, and at the 42nd Annual J. P. Morgan Healthcare Conference on January 8, 2024. The presentations will be webcast live and can be accessed at Investor.Incyte.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
conferences
News

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Rhea-AI Summary
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) announced the successful results from the Phase 2 AGAVE-201 trial of axatilimab for chronic GVHD. The trial met its primary endpoint, with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment. The data were featured in the Plenary Scientific Session at the 65th American Society of Hematology Annual Meeting 2023. Incyte and Syndax expect to file a Biologics License Application (BLA) for axatilimab by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
none
-
News

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

Rhea-AI Summary
Incyte (Nasdaq:INCY) will present more than 40 abstracts at the ASH 2023 conference, featuring data from its hematology and oncology products. The Plenary Scientific Session will showcase the results of the AGAVE-201 trial evaluating axatilimab in patients with chronic GVHD. Incyte will also host an analyst and investor event to discuss the key data presentations at ASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
News

Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Rhea-AI Summary
Incyte reports Q3 2023 financial results with total revenues of $919 million, a 12% YoY increase. Jakafi net product revenues were $636 million, up 3% YoY. Opzelura cream net product revenues were $92 million, up 141% YoY. The company achieved positive results in a Phase 2 study of povorcitinib in prurigo nodularis and plans to initiate a Phase 3 study in 2024. Incyte also provided updates on its clinical development portfolio and highlighted progress in myeloproliferative neoplasms (MPNs).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
earnings
News

Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023

Rhea-AI Summary
Incyte recognized as a top employer for the sixth consecutive year by Science magazine, ranking second on the list and praised for loyal employees and social responsibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
none
-
News

Incyte to Present at Upcoming Investor Conferences

Rhea-AI Summary
Incyte to present at investor conferences in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
-
News

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

Rhea-AI Summary
Incyte to present new data from its oncology portfolio at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
none
News

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Rhea-AI Summary
Incyte announces positive results from Phase 3 study of ruxolitinib cream in children with atopic dermatitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none

FAQ

What is the current stock price of Incyte (INCY)?

The current stock price of Incyte (INCY) is $72.11 as of February 21, 2025.

What is the market cap of Incyte (INCY)?

The market cap of Incyte (INCY) is approximately 13.8B.

What is Incyte Genomics Inc. known for?

Incyte Genomics Inc. is known for its development and commercialization of proprietary therapeutics, primarily focused on oncology and dermatology.

Where is Incyte Genomics Inc. headquartered?

Incyte Genomics Inc. is headquartered in Wilmington, Delaware.

What is Jakafi?

Jakafi is Incyte's lead drug, used to treat rare blood cancers and graft versus host disease, in collaboration with Novartis.

Which drugs has Incyte marketed?

Incyte has marketed drugs including Olumiant for rheumatoid arthritis, Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma.

What is Opzelura used for?

Opzelura is Incyte’s first dermatology product, approved for atopic dermatitis in 2021 and for vitiligo in 2022.

Does Incyte collaborate with other pharmaceutical companies?

Yes, Incyte has established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of its compounds.

How many employees work at Incyte?

Incyte employs over 625 professionals.

What is Incyte's vision?

Incyte's vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs.

How can I get more information about Incyte?

More information about Incyte can be found on their corporate website at www.incyte.com.

What areas does Incyte's pipeline cover?

Incyte's pipeline includes a broad array of oncology and dermatology programs.
Stock INCY logo
Incyte Corp

Nasdaq:INCY

INCY Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

INCY Stock Data

13.81B
189.15M
2.05%
97.41%
2.62%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON